Helix Launches Whole Exome+® Sequencing for Patients with Rare and Unexplained Genetic Conditions

Helix, the leading enterprise genomics platform, today announced the availability of Whole Exome+® Sequencing (WES+), a comprehensive diagnostic sequencing test now available to ordering providers ...
RTTNews

Bionano Announces Proposed Medicare Coverage For Genome-Wide Hematologic Cancer Testing

Bionano Laboratories has validated its OGM-Dx HemeOne diagnostic test for hematologic malignancy analysis. The test is expected to be eligible for coverage under the proposed LCD once the policy is ...

Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms

The draft LCD would provide coverage for genome-wide assays that detect copy number alterations and structural variants when testing informs diagnosis or clinical management in accordance with current ...

Sepsis Diagnostics Market worth $1.22 billion by 2031 - Exclusive Report by MarketsandMarkets™

According to MarketsandMarkets™, the Sepsis Diagnostics Market is projected to reach USD 1.22 billion by 2031 from USD 0.83 ...
Rare Disease Advisor

Follow-Up Testing May Elucidate Atypical Prenatal cfDNA Results

Follow-up testing after atypical cell-free DNA (cfDNA) screening, sometimes used in FNAIT assessment, may identify genetic ...

Sepsis Diagnostics Market worth $1.22 billion by 2031 - Exclusive Report by MarketsandMarkets

According to MarketsandMarkets, the Sepsis Diagnostics Market is projected to reach USD 1.22 billion by 2031 from USD 0.83 billion in 2026, at a ...
clpmag

Helix Launches Whole Exome Sequencing Test Combining Exome, Mitochondrial, and Digital Karyotype Analysis

Whole Exome+ Sequencing integrates exome, mitochondrial, and digital karyotype analysis, aiming to reduce standalone CMA ...

Genomic Testing Market Set for Strong Growth Through 2035, Fueled by Precision Medicine, Lower Sequencing Costs and Expanding Clinical Applications

NGS, personalized medicine and early cancer detection are driving adoption, creating opportunities in liquid biopsy, precision oncology, drug development and recurring consumables.Dublin, Sept. (GLOBE ...

Drug Discovery Technologies Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook

Opportunities center on AI-driven design, high-throughput screening, bioinformatics, RNA therapies, nanotechnology, pharmacogenomics and integrated R&D platforms.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE ...
Drug Target Review

Sample collection: the overlooked key to genomic study success

As genomic studies become larger and more diverse, sample collection can make or break their success. Discover why collection ...
eLife

Persistent Microglial HIV Infection Drives Neuroinflammation Despite Viral Suppression: Insights from Rapid Postmortem Brain Biopsies

This is a valuable study that contributes to our understanding of transcriptomic responses in microglia to HIV infection in the human brain. The evidence provided remains incomplete, and further ...
Journal of Nuclear Medicine

Cell Surface Expression and PET Imaging Establish DLL3 as a Clinically Actionable Target in Neuroblastoma

In adult neuroendocrine malignancies, including small cell lung cancer, Delta-like ligand 3 (DLL3) is a validated therapeutic target. DLL3 is expressed in neuroblastoma, a pediatric cancer of ...